To determine the degree of platelet inhibition from the use of P2Y12 inhibition drug therapies known as thienopyridines. These include Clopidogrel (Plavix), Prasugrel, Ticlopidine (Ticlid), and Ticagrelor.

The objectives of this review are to discuss the pharmacological limitations of the P2Y12 inhibitor clopidogrel, and describe the novel alternative P2Y12 inhibitors prasugrel and ticagrelor and the clinical implications of the introduction of these new medicines.

Platelet activation during disease states leads to vascular occlusion and ischemic damage. The P2Y 12 receptor, activated by ADP, plays a central role in platelet activation and is the target of P2Y 12 receptor antagonists that have proven therapeutic value.

The platelet P2Y12 receptor (P2Y12R) for adenosine 5'diphosphate (ADP) plays a central role in platelet function, hemostasis, and thrombosis. Patients with inherited P2Y12R defects display mild-to-moderate bleeding diatheses.

2024年7月14日 · Antiplatelet medicines work to make your platelets less sticky and thereby help prevent blood clots from forming in your arteries. Aspirin is an antiplatelet medicine that may be used. P2Y12 receptor blockers are another group of antiplatelet medicines.

P2Y12 is a G-protein-coupled receptor that is activated upon ADP binding. Considering its well-established role in platelet activation, blocking P2Y12 has been used as a therapeutic strategy for antiplatelet aggregation in cardiovascular disease ...

2017年10月30日 · Dual antiplatelet therapy with aspirin and a P2Y 12 inhibitor is the treatment of choice for the prevention of atherothrombotic events in patients with acute coronary syndromes and for those undergoing percutaneous coronary interventions.

2024年12月25日 · P2RY12 (Purinergic Receptor P2Y12) is a Protein Coding gene. Diseases associated with P2RY12 include Bleeding Disorder, Platelet-Type, 8 and Bleeding Disorder Due To P2y12 Defect. Among its related pathways are GPCR downstream signalling and Class A/1 (Rhodopsin-like receptors).

The platelet P2Y12 receptor (P2Y12R) for adenosine 5′diphosphate (ADP) plays a central role in platelet function, hemostasis, and thrombosis. Patients with inherited P2Y12R defects display mild‐to‐moderate bleeding diatheses.

The P2Y12 is an ADP receptor in platelets, which is an essential part of platelet activation (Hechler and Gachet, 2015). Stimulation of P2Y12 by ADP, which is released from dense granules of activated platelets, results in sustained platelet aggregation and secretion (Jin and Kunapuli, 1998).